• 

  BHU study: Over 30 per cent of Covaxin recipients report adverse events

  India | May 16, 2024 23:41 IST

  The one-year follow-up study, involving 926 participants, highlighted the long-term safety of the BBV152 vaccine, with serious adverse events like stroke and Guillain-Barre syndrome reported in one percent of recipients.

• 

  Centre rejects media reports claiming approval for Covaxin rushed due to political pressure

  India | November 17, 2022 14:46 IST

  The government said the scientific approach and prescribed norms adhered to in approving Covid-19 vaccines for Emergency Use Authorization.

• 

  COVID: 50 million Covaxin doses set to expire due to poor off take

  India | November 06, 2022 13:41 IST

  Covaxin news: “Covaxin doses in vials are set to expire during early 2023, resulting in losses for the company,” said sources.

• 

  Japan has approved Covaxin booster dose for travellers: Bharat Biotech

  India | August 05, 2022 22:56 IST

  In April this year, the Japanese government announced including Covaxin in its list of recognized vaccines to further facilitate travel from India.

• 

  Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech

  India | June 17, 2022 12:25 IST

  A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer-reviewed high impact factor journal.

• 

  Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

  India | June 15, 2022 13:46 IST

  The findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer-reviewed.

• 

  Germany recognises Bharat Biotech's Covaxin for travel from June 1

  India | May 26, 2022 12:07 IST

  The DCGI in April also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.

• 

  As Covid cases rise, govt plans to cut waiting period for booster shots to 6 months

  India | April 28, 2022 10:26 IST

  At present, the gap between the second Covid jab and the precaution dose is nine months.

• 

  COVID vaccination: DCGI asks Bharat Biotech to provide more data on Covaxin for below 12-year-olds

  India | April 22, 2022 14:09 IST

  This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years.

• 

  Bharat Biotech to soon rectify issues raised by WHO on Covaxin, say sources

  India | April 05, 2022 6:58 IST

  Recently, in a statement on WHO's suspension of Covaxin, Bharat Biotech said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."

• 

  Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies

  India | April 04, 2022 10:10 IST

  Earlier on Sunday, Bharat Biotech had said it had nothing else to add to an earlier statement where it said it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.

Advertisement
• 

  No impact on efficacy and safety of Covaxin: Bharat Biotech after WHO suspension

  India | April 03, 2022 9:48 IST

  The vaccine manufacturer has further said that the company is slowing down the production of Covaxin for facility optimization.

• 

  Bharat Biotech says slowing down Covaxin production for facility optimisation

  India | April 01, 2022 23:20 IST

  The company said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.

• 

  Covaxin to be evaluated as COVID-19 vaccine candidate in US, says Bharat Biotech

  India | February 19, 2022 21:11 IST

  Covaxin has already been granted Emergency Use Listing (EUL) in 13 countries.

• 

  Bharat Biotech gets approval for intranasal Covid-19 booster dose trials

  India | January 28, 2022 15:56 IST

  An intranasal vaccine as a booster dose if becomes a reality would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.

• 

  Covishield, Covaxin get regular market approval for use in adult population

  India | December 15, 2022 15:27 IST

  The DCGI approval came after the Subject Expert Committee (SEC) on COVID-19 recommended granting regular market approval to Covishield and Covaxin.

• 

  Each dose of Covishield, Covaxin likely to be capped at Rs 275 upon market approval

  India | December 15, 2022 15:30 IST

  Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.

• 

  MVA wins Maharashtra Nagar Panchayat polls but BJP emerges single largest party

  India | January 19, 2022 23:22 IST

  The BJP emerged as the single largest party bagging 384 seats against the MVA tally of 944 comprising Nationalist Congress Party's 344, Congress' 316 and Shiv Sena's 284 seats.

• 

  Covishield, Covaxin get govt expert panel's recommendation for regular market approval

  India | January 20, 2022 9:31 IST

  Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective COVID-19 vaccines Covishield and Covaxin.

• 

  Covaxin now universal vaccine for adults, children: Bharat Biotech

  India | January 14, 2022 7:26 IST

  Earlier, Hyderabad-based Hyderabad-based vaccine manufacturer had claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.